Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Balancing costs, efficacy, and side effects.

J Avorn1

  • 1Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Pharmacoeconomics
|December 9, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.

Clinical pharmacology and therapeutics·2015
Same author

Clinical and regulatory features of drugs not initially approved by the FDA.

Clinical pharmacology and therapeutics·2013
Same author

Defining "innovativeness" in drug development: a systematic review.

Clinical pharmacology and therapeutics·2013
Same author

Drug labels: a flawed source of data for studying orphan drug approvals.

Clinical pharmacology and therapeutics·2012
Same author

Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2012
Same author

Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.

BMJ (Clinical research ed.)·2012
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Most drug approval processes lack comparative data on efficacy, safety, and cost. A systematic approach is needed to compare similar drugs, enabling informed therapeutic choices for better healthcare efficiency.

Area of Science:

  • Health economics
  • Pharmacoeconomics
  • Clinical pharmacology

Background:

  • Current drug approval processes often omit comparative data on efficacy, safety, and cost.
  • This data gap complicates informed decision-making for clinicians, patients, and policymakers.
  • Increasing cost-containment pressures exacerbate the challenge of optimal drug selection without adequate comparative evidence.

Purpose of the Study:

  • To advocate for a systematic process comparing similar drugs across efficacy, safety, and cost dimensions.
  • To highlight the need for comprehensive data to support informed therapeutic choices.
  • To emphasize the potential for improved healthcare efficiencies through rational drug use.

Main Methods:

  • Utilizing a multi-methodological approach including randomized controlled trials.

Related Experiment Videos

  • Incorporating pharmacoepidemiological studies to gather real-world evidence.
  • Employing cost-effectiveness analyses to evaluate economic value.

    • Main Results:

    • Current drug approval frameworks are insufficient for comparative decision-making.
    • A structured comparison of drugs on efficacy, safety, and cost is essential.
    • Such comparative data, distinct from registration, empowers stakeholders.

    Conclusions:

    • A systematic evaluation of drug efficacy, safety, and cost is crucial for informed therapeutic choices.
    • This approach supports rational drug use and enhances healthcare system efficiencies.
    • Investment in comparative drug research offers substantial long-term economic benefits.